NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PHAR

Pharming Group N.V. ADR

Jun 30 • 04:00PM ET

10.69

Dollar change -0.31
Percentage change -2.85	%

Healthcare • Biotechnology • Netherlands • NASD

Peers: VRTX AMGN BBIO BIIB GILD REGN NBIX INCY RARE QURE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.20	Insider Own	-	Shs Outstand	68.03M	Perf Week	3.59%
Market Cap	727.24M	Forward P/E	-	EPS next Y	-0.11	Insider Trans	-	Shs Float	-	Perf Month	2.99%
Enterprise Value	740.40M	PEG	-	EPS next Q	-0.10	Inst Own	1.32%	Short Float	-	Perf Quarter	21.48%
Income	-13.29M	P/S	2.27	EPS this Y	16.07%	Inst Trans	-81.54%	Short Ratio	0.32	Perf Half Y	14.70%
Sales	320.29M	P/B	3.40	EPS next Y	21.03%	ROA	-3.15%	Short Interest	0.00M	Perf YTD	6.21%
Book/sh	3.15	P/C	6.78	EPS next 5Y	-	ROE	-6.33%	52W High	12.61 -15.23%	Perf Year	24.35%
Cash/sh	1.58	P/FCF	266.39	EPS past 3/5Y	- -	ROIC	-4.10%	52W Low	6.65 60.75%	Perf 3Y	10.78%
Dividend Est.	-	EV/EBITDA	38.99	Sales past 3/5Y	14.32% 9.42%	Gross Margin	90.65%	Volatility	6.03% 3.72%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.31	EPS Y/Y TTM	-27.69%	Oper. Margin	1.96%	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.00	Sales Y/Y TTM	23.92%	Profit Margin	-4.15%	RSI (14)	50.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	-17.02%	SMA20	-3.46%	Beta	0.03	Target Price	26.02
Payout	-	Debt/Eq	0.56	Sales Q/Q	42.73%	SMA50	8.37%	Rel Volume	8.39	Prev Close	11.00
Employees	-	LT Debt/Eq	0.52	Earnings	May 08 BMO	SMA200	20.39%	Avg Volume	3.96K	Price	10.69
IPO	Dec 23, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-780.00% 16.77%	Trades		Volume	33,193	Change	-2.85%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-24	Initiated	Jefferies	Buy	$14

Jun-24-25 01:00AM	Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis (GlobeNewswire) +8.58%
Jun-11-25 11:15AM	Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders (GlobeNewswire)
May-28-25 02:00AM	Pharming Group to participate in June investor conferences (GlobeNewswire) -7.22%
May-08-25 01:00AM	Pharming Group reports first quarter 2025 financial results and provides business update (GlobeNewswire) +11.22%
Apr-30-25 11:45AM	Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director (GlobeNewswire)
09:00AM	Loading…
Apr-25-25 09:00AM	Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire)
08:09AM	SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-24-25 10:55AM	Pharming announces positive recommendation from NICE for Joenja (TipRanks)
02:00AM	Pharming Group to report first quarter 2025 financial results on May 8 (GlobeNewswire)
Apr-23-25 03:30AM	Pharming receives positive recommendation from NICE for Joenja (leniolisib) as a treatment for APDS (GlobeNewswire)
Apr-03-25 01:00AM	Pharming Group announces the filing of its 2024 Annual Report and Form 20-F (GlobeNewswire) -8.11%
Apr-01-25 08:45AM	Pharming Group: Small Dutch Company With Strong Revenues (Seeking Alpha)
Mar-28-25 03:00AM	Pharming Group to participate in April investor conferences (GlobeNewswire)
Mar-20-25 02:00AM	Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation (GlobeNewswire)
Mar-13-25 02:00AM	Pharming Group reports fourth quarter and full year 2024 financial results and provides business update (GlobeNewswire) +12.92%
09:15AM	Loading…
Mar-04-25 09:15AM	Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders (GlobeNewswire)
Feb-28-25 02:00AM	Pharming Group to participate in March investor conference (GlobeNewswire)
Feb-27-25 02:00AM	Pharming Group to report fourth quarter and full year 2024 financial results on March 13 (GlobeNewswire) -6.62%
Feb-20-25 04:00PM	Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent (GlobeNewswire) +5.05%
Feb-10-25 02:00AM	Pharming Group to participate in February investor conference (GlobeNewswire)
Feb-07-25 04:00PM	Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period (GlobeNewswire)
Jan-21-25 12:00PM	Pharming Group to convene Extraordinary General Meeting of Shareholders (GlobeNewswire)
01:00AM	Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer (GlobeNewswire)
Dec-15-24 01:45PM	Pharming announces public cash offer to the shareholders of Abliva AB (GlobeNewswire)
Dec-11-24 01:00AM	Pharming announces positive topline data in pediatric clinical trial of leniolisib (GlobeNewswire) +6.07%
Nov-05-24 02:00AM	Pharming Group to participate in November investor conference (GlobeNewswire)
Oct-24-24 01:00AM	Pharming Group reports third quarter 2024 financial results and provides business update (GlobeNewswire) -7.37%
Oct-10-24 02:00AM	Pharming Group to report third quarter 2024 financial results on October 24 (GlobeNewswire)
01:00AM	Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation (GlobeNewswire)
Sep-26-24 01:00AM	Pharming announces marketing authorization in the U.K. for Joenja (leniolisib) (GlobeNewswire)
01:00AM	Loading…
Sep-04-24 01:00AM	Pharming Group to participate in September investor conferences (GlobeNewswire)
Aug-01-24 01:00AM	Pharming Group reports second quarter and first half 2024 financial results and provides business update (GlobeNewswire) -8.40%
Jul-18-24 02:00AM	Pharming Group to report second quarter and first half 2024 financial results on August 1 (GlobeNewswire)
Jun-03-24 02:00AM	Pharming Group to participate in June investor conferences (GlobeNewswire)
May-30-24 04:44PM	Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union (GlobeNewswire)
May-21-24 11:30AM	Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
May-20-24 02:00AM	Pharming Group to participate in May investor conference (GlobeNewswire)
May-15-24 01:00AM	Pharming Group announces the early redemption of the remaining outstanding 125 million convertible bonds due 2025 (GlobeNewswire)
May-08-24 06:52AM	PHAR Stock Earnings: Pharming Reported Results for Q1 2024 (InvestorPlace)
06:16AM	Pharming Group uproots angioedema gene therapy collab with Orchard (FierceBiotech.com)
01:00AM	Pharming Group reports first quarter 2024 financial results and provides business update (GlobeNewswire)
May-02-24 06:00AM	Genomenon Partners with Pharming to Advance APDS Diagnosis (PR Newswire)
Apr-24-24 02:00AM	Pharming Group to report first quarter 2024 financial results on May 8 (GlobeNewswire)
01:00AM	Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD ) 2024 Rare Impact Awards (GlobeNewswire)
Apr-22-24 05:29AM	Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains? (Zacks)
Apr-19-24 12:43PM	Pharming Group announces the repurchase of outstanding 125 million convertible bonds due 2025 (GlobeNewswire) +7.18%
Apr-18-24 09:04AM	Pharming Group announces the placement of 100 million convertible bonds due 2029 (GlobeNewswire) -8.26%
02:00AM	Pharming Group announces the launch of an offering of approximately 100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding 125 million convertible bonds due 2025 (GlobeNewswire)
Apr-08-24 01:00AM	Pharming announces completion of enrollment in pediatric clinical trial of leniolisib (GlobeNewswire)
Apr-04-24 02:30AM	Pharming Group announces the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
01:00AM	Pharming Group announces the filing of its 2023 Annual Report and Form 20-F (GlobeNewswire)
Apr-03-24 02:00AM	Pharming Group to participate in April investor conferences (GlobeNewswire)
Mar-14-24 02:00AM	Pharming Group reports fourth quarter and full year 2023 financial results (GlobeNewswire)
Feb-29-24 02:00AM	Pharming Group to report fourth quarter and full year 2023 financial results on March 14 (GlobeNewswire)
Feb-08-24 02:00AM	Pharming Group to participate in February investor conferences (GlobeNewswire) -7.19%
Jan-08-24 01:29AM	Pharming Group Projects 2023 Total Revenues To Rise 19% (RTT News)
01:00AM	Pharming Group announces updated full year 2023 guidance and Joenja U.S. launch update (GlobeNewswire)
Dec-13-23 01:00AM	Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) (GlobeNewswire)
Nov-21-23 01:00AM	Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib (GlobeNewswire)
Nov-10-23 08:51AM	Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval (GlobeNewswire) -10.78%
Nov-07-23 02:00AM	Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting (GlobeNewswire)
Nov-01-23 03:00AM	Pharming Group to participate in November investor conferences (GlobeNewswire)
Oct-26-23 01:00AM	Pharming Group reports third quarter 2023 financial results (GlobeNewswire) +5.00%
Oct-12-23 02:00AM	Pharming Group to report third quarter 2023 financial results on October 26 (GlobeNewswire)
Sep-25-23 10:00AM	Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders (GlobeNewswire)
Aug-24-23 02:00AM	Pharming Group to participate in September investor conferences (PR Newswire)
Aug-14-23 01:00AM	Pharming Group to convene Extraordinary General Meeting of Shareholders (PR Newswire)
Aug-09-23 01:00AM	Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan (PR Newswire)
Aug-03-23 01:00AM	Pharming Group reports second quarter and first half 2023 financial results (PR Newswire)
Jul-18-23 01:00AM	Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board (PR Newswire) -6.34%
Jul-13-23 02:00AM	Pharming Group to report second quarter and first half 2023 financial results on August 3 (PR Newswire) +6.29%
Jun-01-23 01:00AM	Pharming announces sale of priority review voucher (PR Newswire)
May-25-23 02:00AM	Pharming Group to attend the following Investor Conferences in June (PR Newswire)
May-17-23 11:28AM	Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders (PR Newswire)
May-11-23 01:00AM	Pharming Group reports financial results for the first quarter of 2023 (PR Newswire) -20.36%
Apr-26-23 02:00AM	Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023 (PR Newswire)
Apr-19-23 02:00AM	Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023 (PR Newswire) -5.80%
01:36AM	Notice of First Quarter 2023 Results (PR Newswire)
Apr-13-23 06:00AM	Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023 (PR Newswire)
Apr-11-23 01:00AM	Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S. (PR Newswire)
Apr-05-23 02:00AM	Pharming Group convenes the Annual General Meeting of Shareholders 2023 (PR Newswire)
01:00AM	Pharming Group announces the filing of its 2022 Annual Report and Form 20-F (PR Newswire)
Mar-30-23 10:39AM	Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days (PR Newswire)
Mar-24-23 02:51PM	Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS (PR Newswire) +32.74%
Mar-13-23 05:43AM	Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcement (PR Newswire)
03:15AM	Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement (PR Newswire)
Mar-12-23 03:55PM	Dutch biotech Pharming says it held $45 mln in collapsed SVB (Reuters)
02:30PM	Pharming Group issues statement regarding the events surrounding Silicon Valley Bank (PR Newswire)
Feb-28-23 01:00AM	Notice of Full Year 2022 financial results (PR Newswire)
Feb-21-23 01:00AM	Pharming announces first patient enrolled in pediatric clinical trial of leniolisib (PR Newswire)
Feb-16-23 01:00AM	Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe (PR Newswire) -10.51%
Dec-15-22 08:55AM	Pharming Highlights Interim Data From Rare Immune Deficiency Study (Benzinga)
01:00AM	Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (PR Newswire)
Dec-12-22 08:50AM	Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Dec-07-22 01:00AM	Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood (PR Newswire)
Dec-01-22 09:40AM	Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-28-22 02:36AM	Investing in Pharming Group (AMS:PHARM) a year ago would have delivered you a 59% gain (Simply Wall St.)
Nov-23-22 08:50AM	Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why (Zacks)
01:00AM	Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting (PR Newswire)
Nov-08-22 12:20PM	Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates? (Zacks) -5.26%

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST, Joenja, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHAR

Pharming Group N.V. ADR

Upgrade your FINVIZ experience